All In Biotech

Drug Trial Radar · NCT06629402

Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)

A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Oct 5, 2023

Primary completion

Nov 14, 2023

Study completion Nov 15, 2023

Sponsor

Lead sponsor
Ensysce BiosciencesIndustry
Sponsor type
Industry
Collaborators
Dr. Vince Clinical Research
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the onset of analgesia following administration of a single oral dose of PF614 (50 mg or 100 mg) or placebo in healthy male subjects in an experimental pain model (cold pressor test \[CPT\]).

Conditions

  • Acute Pain

Interventions

  • PF614Drug

    Experimental oxycodone prodrug

  • PlaceboDrug

    Inactive medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline (pre-dose) in Time to Pain Onset (defined as time to first pain)Time frame: 6 hours
  2. Change from Baseline in Pain Tolerance (defined as latency time required for removal of hand from water bath)Time frame: 6 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr. Vince Clinical Research

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.